Know Cancer

forgot password

A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-over, Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, In Patients With Recurrent Osteosarcoma Localized to the Lung

Phase 2
15 Years
74 Years
Open (Enrolling)

Thank you

Trial Information

A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-over, Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, In Patients With Recurrent Osteosarcoma Localized to the Lung

Further details provided by SARC (Sarcoma Alliance for Research through Collaboration):

After complete surgical removal of their cancer, patients will be randomly assigned to
receive either Saracatinib or placebo (a sugar pill) throughout the study. Patients will
take Saracatinib (or placebo) once daily by mouth for a total of 364 days. The duration of
treatment is divided into 13 cycles, 28 days each cycle with no breaks in between.

Patients will be seen for interim medical history, physical exam and laboratory studies
prior to each cycle. To monitor for recurrence of tumor, patients will undergo thoracic CT
scans at 3-4 weeks, 6-8 weeks, at 3 months, at 6 months, at 9 months, at 12 months, then
every 6 months up to 2 years, and then every year up to 5 years after starting treatment.
An electrocardiogram (ECG) will be taken at 3 months, and a bone scan will be performed at
12 months.

Patients who recur in the lung while on-study and who are thought to be amenable to complete
surgical resection will be able to find out if they were receiving placebo or saracatinib.
Those patients who were receiving placebo may then have the option of undergoing surgical
resection. If fully resected of all recurrent disease,they will be given the option of
receiving oral therapy with saracatinib. Saracatinib will be administered as a once daily,
oral dose of 175 mg, for a 28-day cycle, with no breaks between cycles. The duration of
treatment with saracatinib will be thirteen 28-day cycles (364 days total). If complete
resection of all lung nodules is not achieved, the patient will be removed from the study.

Patients who recur in locations other than the lung while on-study will be taken off study
at that time.

Blood and tumor samples for research purposes will be collected at the time the tumor is

After completing all 13 cycles, patients will be followed for approximately every 3 months
until 2 years from starting treatment, then approximately every 6 months until 4 years from
starting treatment, and once at year 5.

Inclusion Criteria:

- Patient had recurrence of osteosarcoma, localized to the lungs, had complete surgical
removal of all lung nodules are eligible for enrollment.

- Patient with suspected recurrence of osteosarcoma but who has not had surgery is
eligible for enrollment but will not be randomized to receive study medication until
deemed fully eligible following surgical removal of all lung nodules.

- Patient had histological confirmed diagnosis of osteosarcoma of the recurrent sample.

- Patient had recurrence of osteosarcoma in the lung following standard therapy
including: adriamycin, cisplatin, ifosfamide and methotrexate.

- Patient is ≥ 15 and < 75 years of age.

- Weight ≥ 34 kg.

- ECOG performance score of 0-2.

- Adequate bone marrow function.

- Adequate renal function.

- Adequate hepatic function.

- Adequate cardiac function.

- Women of childbearing potential must have had a negative pregnancy test (urine or
serum) ≤ 7 days prior to enrollment, and willingness to use an acceptable method of
contraception during participation in the study and for 3 months after the last dose.

- Randomization must occur ≤ 6 weeks after complete surgical resection.

- Patient or legal guardian has signed informed consent.

Exclusion Criteria:

- Presence of metastatic disease in other locations in addition to the lung.

- Disruption of the lung pleura by tumor.

- Paget's disease.

- Patient currently using, or has previously used CYP3A4 inducers or inhibitors within
2 to 14 days prior to the initiation of oral therapy.

- Known hypersensitivity to other Src/Abl non-receptor kinase inhibitors.

- Evidence of interstitial lung disease.

- Any concurrent condition which in the investigator's opinion makes it undesirable for
the patient to participate in the trial or which would jeopardize compliance with the

- Myocardial infarction within one year prior to study entry.

- Bleeding diathesis, resulting in symptomatic bleeding.

- Patient is pregnant or nursing/breast-feeding.

- Patient received chemotherapy, biological or investigational agent ≤ 28 days prior to

- Patient experiencing unresolved toxicity ≥ CTCAE grade 2 (except alopecia) from
previous agents.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Outcome Measure:

To determine the progression free survival rate among patients treated with Saracatinib and placebo.

Outcome Time Frame:

Evaluation for recurrence/progression will be made every 3 months for the 1st year, then every 6 months up to 2 years, then every year up to 5 years after starting treatment.

Safety Issue:


Principal Investigator

Kristin Baird, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Cancer Institute - Pediatric Oncology Branch


United States: Food and Drug Administration

Study ID:




Start Date:

March 2009

Completion Date:

September 2014

Related Keywords:

  • Osteosarcoma
  • AZD0530
  • Saracatinib
  • Osteosarcoma
  • Recurrent
  • Localized
  • to the Lung
  • Osteosarcoma



University of AlabamaBirmingham, Alabama  
University of MichiganAnn Arbor, Michigan  48109-0624
UCSFSan Francisco, California  941430324
University of Iowa Hospitals and ClinicsIowa City, Iowa  52242
University of Pittsburgh Cancer InstitutePittsburgh, Pennsylvania  15213
Stanford UniversityStanford, California  94305
Dana-Farber Cancer InstituteBoston, Massachusetts  02115
USC/Norris Comprehensive Cancer Center and HospitalLos Angeles, California  90033-0804
Children's Hospital Los AngelesLos Angeles, California  90027-0700
St. Jude Children's Research HospitalMemphis, Tennessee  38105-2794
Cincinnati Children's Hospital Medical CenterCincinnati, Ohio  45229-3039
University of FloridaGainesville, Florida  32610-0277
University of MiamiMiami, Florida  33136
Indiana UniversityIndianapolis, Indiana  46202
Johns Hopkins Sidney Kimmel Comprehensive Cancer CenterBaltimore, Maryland  21231
Sarcoma Oncology CenterSanta Monica, California  90403
National Cancer InstituteBethesda, Maryland  20892-1922
UCLA/Mattel's Children's HospitalLos Angeles, California  90095
Pennsylvania Hematology Oncology AssociatesPhiladelphia, Pennsylvania  19106
Seattle Cancer Care Alliance/University of Washington Medical CenterSeattle, Washington  98109